Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors

Table 4 Comparison of baseline characteristics between different recurrence patterns in patients with GBM

Characteristics	Local(N = 52)	Non-local(N = 14)	p-value
Age(years), n (%)			0.491
≤ 50	12 (23.1)	5 (35.7)
Gender, n (%)			0.745
Female	15 (28.8)	5 (35.7)
BMI, n (%)			0.763
≤ 24	22 (42.3)	7 (50.0)
Extent of resection, n (%)			0.708
GTR	43 (82.7)	11 (78.6)
Laterality, n (%)			0.812
Left	26 (50)	9 (64.3)
Right	21 (40.4)	4 (28.6)
Bilateral	5 (9.6)	1 (7.1)
SVZ involvement, n (%)			0.006
Yes	19 (36.5)	11 (78.6)
Cerebral midline involvement, n (%)			1.000
Yes	31 (59.6)	8 (57.1)
Brain cortex involvement, n (%)			0.753
Yes	16 (30.8)	5 (35.7)
MGMT promoter, n (%)			0.686
Methylated	11 (44.0)	4 (57.1)
TERT promoter, n (%)			0.043
Mutated	18 (85.7)	3 (42.9)
Ki-67 index, n (%)			0.753
≤ 20	16 (30.8)	5 (35.7)
ATRX, n (%)			1.000
Mutated	36 (87.8)	11 (91.7)
BRAF, n (%)			1.000
Mutated	3 (7.7)	1 (9.1)
P53 expression, n (%)			1.000
Mutated	34 (75.6)	8 (72.7)
CD34, n (%)			0.762
Mutated	27 (60.0)	7 (53.8)
Time of radiation, n (%)			1.000
≤ 42d	30 (57.7)	8 (57.1)

GTR Gross total resection, STR Subtotal resection, GBM Glioblastomas, MGMT O6-methylguanine-DNA-methyltransferase gene, TERT Telomerase reverse transcriptase, SVZ Subventricular zone, BRAF v-raf murine sarcoma viral oncogene homolog B1, p53 Protein 53, CD34 Hematopoietic progenitor cell antigen CD34; In bold: p value less than 0.05

ISSN: 1748-717X